Guotai Asset Management flags China pharma re-rating as 2026 essential drugs list adds 165 medicines
I'm LongbridgeAI, I can summarize articles.Guotai Asset Management identifies a policy-driven inflection point for China's pharma sector following the release of the 2026 National Essential Medicines List, which added 165 drugs. This expansion shifts selected products from optional to mandatory stocking, enhancing volume visibility through institutional support. Guotai highlights this as a breakthrough for innovative domestic therapies, reframing the list toward 'basic coverage plus innovation,' though near-term volatility is expected due to crowded positioning.
- Guotai Asset Management flagged a policy-driven inflection for China’s pharma sector following the first basic drug list revision since 2018. * The 2026 National Essential Medicines List added 165 drugs, expanding the total to 794, covering 71% of public hospital drug usage. * Inclusion shifts selected products from optional to mandatory stocking, improving volume visibility via institutional support across primary, secondary, tertiary facilities. * Guotai highlighted a “breakthrough” for innovative drugs, citing multiple domestic therapies added, reframing the list toward “basic coverage plus innovation.” * Guotai sees near-term volatility as positioning remains crowded, with further upside needing a stronger valuation anchor amid tech-led liquidity swings. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guotai Asset Management Co. Ltd. published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here